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Background: The majority of diabetic cats in remission have abnormal glucose
tolerance, and approximately one third relapse within 1 year. Greater understanding of
the metabolic characteristics of diabetic cats in remission, and predictors of relapse is
required to effectively monitor and manage these cats.
Objectives: To identify and compare differences in plasmametabolites between diabetic
cats in remission and healthy control cats using a metabolomics approach. Secondly, to
assess whether identified metabolites are predictors of diabetic relapse.
Animals: Twenty cats in diabetic remission for a median of 101 days, and 22 healthy
matched control cats.
Methods: Cats were admitted to a clinic, and casual blood glucose was recorded. After
a 24 h fast, blood glucose concentration was measured, then a blood sample was taken
for metabolomic (GCMS and LCMS) analyses. Three hours later, a simplified intravenous
glucose tolerance test (1 g glucose/kg) was performed. Cats were monitored for diabetes
relapse for at least 9 months (270 days) after baseline testing.
Results: Most cats in remission continued to display impaired glucose tolerance.
Concentrations of 16 identified metabolites differed (P ≤ 0.05) between remission
and control cats: 10 amino acids and stearic acid (all lower in remission cats), and
glucose, glycine, xylitol, urea and carnitine (all higher in remission cats). Moderately
close correlations were found between these 16 metabolites and variables assessing
glycaemic responses (most |r| = 0.31 to 0.69). Five cats in remission relapsed during the
study period. No metabolite was identified as a predictor of relapse.
Conclusion and clinical importance: This study shows that cats in diabetic remission
have abnormal metabolism.
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INTRODUCTION
Diabetic remission, described previously by our group as
maintaining euglycemia for at least two weeks after insulin
therapy has ceased, can be achieved in many newly diagnosed
feline diabetics, with highest remission rates reported in cats with
type 2-like diabetes enrolled in studies with early intervention,
intensive long-acting insulin therapy and low carbohydrate diets
(1, 2). Approximately 25–30% of cats in remission will relapse
and require further insulin therapy (1, 3, 4). In a previous study,
the majority (76%) of diabetic cats in remission had impaired
glucose tolerance (>5 h to return to ≤6.5 mmol/L), and some
(19%) had impaired fasting glucose (≥ 6.6 mmol/L), indicating
that these cats did not have normal glucose metabolism or
clearance (4). Cut points for fasting blood glucose concentrations
and normal glucose tolerance tests were determined based on
data previously published from our laboratory (4, 5). Although
validated cut pointsmay eventually be useful in veterinary clinical
practice to identify cats with altered glucose metabolism and at
risk of developing diabetes, these concepts are largely confined
to human medical practice. Except for the documentation of
impaired glucose tolerance, the wider metabolic disturbances in
diabetic cats in remission are poorly understood.
High-throughput metabolomics assays using mass
spectrometry in combination with gas or liquid chromatography
(GCMS and LCMS, respectively) enable measurement of a wide
range of metabolites in body fluids, and provide a metabolite
profile of the individual. Metabolomics analysis has been widely
used to identify metabolite biomarkers of disease (6). Biomarkers
that can predict the development of glucose intolerance and
development of type 2 diabetes have been described in humans
(7–9). For example, increased serum branched chain amino acids
isoleucine, leucine and valine are associated with increased risk
of development of diabetes (10).
The aims of this study were to compare the plasma
concentration of metabolites between diabetic cats in remission
and healthy control cats using GCMS and LCMS, and secondly
to assess whether differentially expressed metabolites were
predictors of diabetic relapse.
MATERIALS AND METHODS
Study Design
This retrospective and prospective cohort study involved client-
owned diabetic cats in remission presented to a feline-only
veterinary hospital (“remission cats”), and clinically healthy
owned cats presented to the feline-only or university hospital
(“control cats”). Healthy control cats were frequency-matched
with the diabetic cats based on age and body condition
score. Previously insulin-treated diabetic cats in which insulin
administration had ceased were retrospectively identified by
reviewing practice records from January 2005 to April 2010, or
were recruited prospectively from April 2010 to August 2012.
Enrolment criteria were: 1. previously overtly diabetic cats that
required insulin therapy; 2. at least one casual (non-fasted)
glucose concentration ≤6.5 mmol/L (≤117 mg/dl) measured a
minimum of two weeks after insulin administration was ceased;
and 3 absence of clinical signs of diabetes prior to glucose
tolerance testing as part of the current study. Remission date
in this study was defined as 14 days after the date insulin
administration ceased, and only cats in their first remission were
included. At the time of initial diagnosis of diabetes, cats were
only tested for other specific types of diabetes if they had relevant
clinical signs. The cats in this cohort were assumed to have type
2 diabetes, unless tests showed otherwise. Other specific types of
diabetes were not an exclusion criteria for this study. Remission
dates for enrolled cats were from April 2006 to August 2012.
Clients filled out a questionnaire on admission that included
type and quantity of foods fed to their cat. Calculations were
made using information on dietary composition provided by the
manufacturers to determine percentages on a dry matter basis
of protein, carbohydrate, and fat estimated to be consumed by
the cats.
After enrolment, all cats (remission and control) were
admitted to the hospital and casual blood glucose recorded. Body
weight and body condition score were recorded, an in-house
urinalysis was performed, and a 3ml jugular sample was collected
and was sent to an external laboratory1 for haematology, serum
biochemistry, serum fructosamine, total thyroxine (T4), and
feline pancreasic lipase immunoreactivity.
Food was withheld for 24 h, and after overnight
hospitalisation, another 3ml blood sample was collected
from the jugular vein for biochemical and metabolomic assay of
plasma samples. Immediately after collection, blood was placed
into an EDTA tube, centrifuged for 8min at 1500 g and plasma
separated into 1ml Eppendorf tubes. Samples were stored at
−80 degrees Celsius until they were transported on dry ice to the
laboratory for analysis.
Additionally, cats had a simplified glucose tolerance test as
previously described (4, 11). This was performed 3 h after blood
collection for metabolomics and catheter placement to minimise
the effects of stress hyperglycaemia (12). Briefly, the fasting
blood glucose concentration was measured using a portable
glucometer2 calibrated for cat blood from samples obtained from
the ear (first preference), paw pad or jugular vein (depending
on cat’s temperament). Following measurement of fasting blood
glucose, an intravenous bolus of glucose (50% glucose wt/vo)
at 1 g/kg was administered over 1min via a cephalic catheter
placed 3 h before the test. Blood glucose was measured 2 h after
glucose administration, and then hourly until blood glucose
concentration was ≤6.5 mmol/L (≤117 mg/dL) or until 9 h after
the test start, whichever occurred first. Time for glucose to return
to baseline was set as time from test start until the first time that
glucose concentration was measured as ≤6.5 mmol/L (4). Food
was withheld for the duration of the glucose tolerance test.
Metabolomic Analyses
Metabolic analyses and metabolite identification were performed
by Metabolomics Australia (Melbourne, VIC, Australia).
1IDEXX Laboratories, Brisbane, QLD, Australia
2AlphaTRAK, Abbott Animal Health (13).
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Gas Chromatography Mass
Spectrometry (GCMS)
Plasma (50 µl) was transferred into a 1.5ml Eppendorf R© tube.
Cold methanol (MeOH)(100 %, 4◦C) (150 µl) and 1 µl of a
quantitative internal standard (13C6-sorbitol/
13C155 N-Valine in
water, 0.2 mg/ml) was added. The mixture was vortexed for
30 s and placed on ice for 10min. Samples were centrifuged at
13,000 rpm for 10min at room temperature (23◦C) to precipitate
protein. A (30 µl) aliquot was transferred into a glass insert and
dried in vacuo for subsequent derivatisation.
Extracted plasma samples were re-dissolved in 10 µl of 30
mg/ml methoxyamine hydrochloride in pyridine and derivatised
at 37◦C for 120min, mixing at 500 rpm. Samples were treated
for 30min with 20 µl N, O-bis-(trimethylsilyl)trifluoroacetamide
(BSTFA) and 2 µl of a retention time standard mixture [0.029%
(v/v) n-dodecane, n-pentadecane, n-nonadecane, n-docosane,
n-octacosane, n-dotriacontane, n-hexatriacontane dissolved in
pyridine], mixing at 500 rpm. Samples were rested for 60min
prior to injection.
Samples (1 µl) were injected using a hot needle technique
into a GC-MS system comprised of a Gerstel 2.5.2 autosampler,
a 7890A Agilent gas chromatograph and a 5975C Agilent
quadrupole MS (Agilent, Santa Clara, USA).
GC was performed on a 30m VF-5MS column with 0.2µm
film thickness and a 10m Integra guard column (Varian,
Inc, Victoria, Australia). Injection temperature was set to
250◦C, MS transfer line 280◦C, the ion source 250◦C and
the quadrupole 150◦C. Helium carrier gas flow rate was set
to 1 ml/min. The following temperature program was used:
start at injection 35◦C, hold for 2min, then a 15◦C/min oven
temperature ramp to 325◦C held for 3min at 325◦C. Data
were evaluated using the Agilent MassHunter Workstation
Software, Quantitative Analysis, Version B.05.00/Build 5.0.291.0
for GCMS. Individual metabolites were identified by matching
mass spectra to the following libraries 1. Max-Planck-Institute
for Plant Physiology library, Golm, Germany (http://csbdb.
mpimp-golm.mpg.de/csbdb/dbma/msri.html) and the in-house
Metabolomics Australia mass spectral library. All matching
mass spectra were additionally verified by determination of
the retention time with authentic standards. Relative response
ratios (area of analyte divided by area of internal standard,
13C6-sorbitol) per volume of plasma were determined for each
metabolite. If a specific metabolite had multiple trimethylsilyl
(TMS) derivatives, the metabolite with the greater detector
response and improved peak shape within the dynamic range of
the instrument was selected.
Liquid Chromatography Mass
Spectrometry (LCMS)
Serum (50 µl) was diluted with acetonitrile (ACN)(150 µl, 0.1%
formic acid) containing internal standards [3C6-sorbitol—(0.5
mg/ml), 13C155 N-valine—(0.5 mg/ml), 2-aminoanthracene (0.25
mg/ml), pentafluorobenzoic acid (0.25mg/ml)] then vortexed for
30 s and placed on ice for 10min. The solution was centrifuged at
13,000 rpm for 5min at 4◦C then the supernatant transferred into
a fresh vial prior to analysis.
An Agilent 6520A ESI-QqTOF-MS with attached Agilent
1200 series HPLC System comprised of Degasser, Pump, Auto-
sampler with attached chiller cooled to 7◦C. Mass spectra were
collected in the positive (POS) and negative (NEG) ionisation
modes across the mass range 70-1700 m/z, at a rate of 1.5–3
spectra/s. Instrument settings were as follows: gas temperature,
300◦C; drying gas, 10 L/min; nebulizer, 40–45 psig; VCap, 3500V;
fragmentor; 150V, Skinner, 65V; OCT 1 RF Vpp, 750V. Agilent
Reference Mass solution was co-infused through dual ionisation
source for online mass calibration.
For reverse phase (RP) chromatography an Agilent Zorbax
Eclipse XDB-C18, 2.1mm x 100mm, 1.8µm column was used
with an injection volume of 5 µl. Solvent (A) 0.1% formic acid in
Milli-Q water and solvent (B) 0.1% formic acid in can was used. A
solvent flow rate of 0.4 ml/min with column temperature of 40◦C
and a 10min linear gradient from 5% solvent (B) to 100% solvent
(B) was used, followed by a 2min hold at 100% solvent (B), then
5min re-equilibration at 5% solvent (B) (total time of 17 min).
Mass features were extracted using Agilent Mass Hunter
Profinder B.06.0 using a recursive feature extraction with the
following settings: for positive ions +H, +Na and +K adducts,
negative ions –H, +Cl adducts, with allowed neutral losses of
H2O and H3PO4; an allowed charge state of 1-2 with a retention
time window of 0.5min and mass window of 15 ppm ±2 mDa.
The data matrix was imported and features aligned using Agilent
Mass Profiler Professional 13.1 (MPP) with the following settings
for mass tolerance of 15 ppm ±2.0 mDa and retention time
window of 0.7min. The imported data was filtered by retaining
entities that were found in at least 50% of any one condition. The
aligned data matrix of neutral mass, retention time and response
was exported and corrected for internal standard error manually
prior to statistical analysis or metabolite identification.
Metabolites were identified in MPP using the ID Browser
B.07.00 and were matched to the Metabolomics Australia in-
house metabolite library using a mass match tolerance of 10
ppm mass error and retention time (RT) tolerance of 0.5min
against authentic standards. For positive ions +H, +Na and
+K adducts; for negative ions –H, +Cl adducts were allowed,
with possible neutral losses of H2O and H3PO4. A match was
accepted when the overall weighted ID score was greater than 80
(maximum score = 100). Tentative identification of metabolites
was undertaken by searching exported neutral mass features
against the METLIN (https://metlin.scripps.edu) and LipidMaps
(www.lipidmaps.org) online databases.
Identification of Relapses in
Remission Cats
After testing, remission cats were monitored for relapse using
casual blood glucose measurements at home or in clinic. Relapse
was defined as a blood glucose ≥11 mmol/L (198 mg/dl) on at
least two occasions together with the presence of clinical signs
consistent with diabetes (e.g., polyuria, polydipsia, polyphagia,
and weight loss). Cats were monitored by observing blood
glucose concentration (either by home monitoring or during
health checks at the clinic) and clinical signs. The study endpoint
was achieved when the cat relapsed, or, for non-relapsing cats,
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when it died from other causes or, for other cats, the most recent
of the last recorded visit in clinic records (either the feline-only
clinic or the practice that referred the cat to that clinic) or the last
contact date with the owner.
Statistical Analyses
Statistical analyses were performed using Stata (versions
13 and 15; StataCorp, College Station, Texas, USA).
Principal component analyses were performed to visualise
and compare the metabolomic data collectively between
remission and control cats using Stata’s -pca- command.
Separate analyses were performed for GCMS, LCMS Reverse
Phase Chromatography Negative Mode Ionisation (RP_NEG)
and LCMS Reverse Phase Chromatorgraphy Positive Mode
Ionisation (RP_POS) compounds using remission and control
cats pooled. Concentrations were log-transformed for principal
component analyses.
For each metabolite, concentrations were compared between
remission and control cats using linear regression with cat age
and body condition score (fitted as a continuous variables), breed
(Burmese or non-Burmese) and sex (male or female; all cats
were neutered), fitted as covariates. Concentrations were log-
transformed before analyses. Coefficients for effects of remission
were exponentiated (i.e., Euler’s number was raised to the
power of the coefficient), and the results interpreted as ratios of
geometric means. These models were fitted using Stata’s -regress-
command. For metabolites where 15 or more of the 41 or 42
cats had the minimum reported concentration, instead of linear
regression, proportions of cats that had concentrations above the
minimum reported concentration were compared using exact
logistic regression, fitted using Stata’s -exlogistic- command. Cat
breed, sex, age and body condition score were fitted as covariates
as described above, and sufficient statistics were used. P-values
were adjusted for multiple comparisons using the Benjamini-
Hochberg step-up false-discovery rate method, implemented
using the Etcetera module (version 3.02) in WinPepi (version
11.48) (14, 15).
To assess whether differences between remission and control
cats were confounded by diet, for compounds that differed
significantly between remission and control cats (P-value
adjusted for multiple comparisons < 0.05), point estimates were
also calculated using the same models using cats that had dietary
data. Additionally, separate models were used adjusting for either
dietary protein % or dietary carbohydrate %. No adjustment for
dietary fat % was performed as the means for this measure were
similar in remission and control cats.
To compare remission and control cats independently of any
effects of dietary carnitine, plasma carnitine concentrations were
also compared between remission and control cats using the
same model as described above excluding cats fed carnitine.
Plasma carnitine concentrations were also compared between
those cats fed and those not fed carnitine (n = 8 in each)
within the remission cat group, again using the same approach
as described above.
Correlations between each of the identified metabolites that
differed significantly between remission and control cats and
each of casual, fasting, and 2 h glucose, time for glucose to return
to baseline, fPLI, and fructosamine were assessed using Pearson’s
correlation coefficients, or for correlations with time for glucose
to return to baseline, Spearman’s correlation coefficients. Fisher’s
transformation was used to calculate 95% confidence intervals.
These were calculated using the -pwcorr-, -spearman- and -ci2-
commands in Stata. P-values for correlation coefficients were
adjusted for assessment of multiple pair-wise correlations in the
same way as described above. For the 22 compounds with p-
values < 0.05 for differences between remission and control
cats adjusted for multiple comparisons, concentrations were
compared between relapsed and non-relapsed cats using linear
regression as for comparisons between remission and control cats
but with no covariates fitted. For each of these 22 compounds, less
than 7 cats had minimal detectable concentrations.
RESULTS
Twenty cats in remission (median time in remission 110 days,
range 10 days to 4 years) and 22 control cats were enrolled
into the study (Table 1). Fourteen remission cats had presumed
type 2 diabetes, four cats had a history of corticosteroid
administration prior to developing clinic signs, one cat had
corticosteroid administration coupled with severe pancreatitis
on diagnosis and another cat had moderate pancreatitis at
diagnosis. Diagnosis of pancreatitis was based on clinical signs
and fPLI measured by an external laboratory. Glucose tolerance
testing (GTT) was unable to be performed on one cat that
had metabolomic testing and it was retained in the study for
some analyses. Data for cat signalment, body condition score
[scale of 1-9 (16)], glucose and fructosamine concentrations and
feline pancreatic lipase immunoreactivity (FPLi) are summarised
in Table 1. All control cats had fasting blood glucose <6.5
mmo/L (<117 mg/dl) and normal glucose tolerance as measured
by blood glucose <6.5 mmol/L at 3 h (4). Of the diabetic
cats in remission, 4/20 (20%) had impaired fasting glucose
concentrations (fasting glucose 119–151 mg/dl vs. normal <117
mg/dl; 6.6–8.4 mmol/L vs. normal <6.5 mmol/L) and 14/19
(74%) had impaired glucose tolerance (Table 1). One remission
cat did not reach the endpoint of glucose <6.5 mmol/L during
its GTT. The lowest measured glucose concentration was 7.3
mmol/L (131 mg/dl) at 9 h after glucose administration, which
was then determined to be its endpoint (4). In four of the
six cats with suspected other specific types of diabetes, it
was associated with corticosteroid administration without a
concurrent diagnosis of pancreatitis, and three of these cats had
impaired glucose tolerance and one had impaired fasting glucose
concentrations. Of the two cats with pancreatitis at the time
of initial diagnosis of diabetes, both (including the one with
concurrent corticosteroid administration) had normal fasting
glucose and glucose tolerance. Six of the 20 remission cats had
International Renal Interest Society (IRIS) stage 2–3 chronic
kidney disease. Of the 42 cats enrolled in the study (20 remission
cats and 22 healthy control cats), GCMS metabolomic data were
not available for 1 control cat and LCMS RP-NEG data were
not available for 1 remission cat. In total, 978 compounds were
statistically analyzed (the 61 compounds from GCMS that were
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TABLE 1 | Signalment, body condition score, fasting and 2 h glucose concentrations during a GTT for cats in diabetic remission and control cats.
Remission (n = 20) Control (n = 22)
SIGNALMENT
Sex Male neutered 12; female spayed 8 Male neutered 12; female spayed 10
Median age at testing (range) 13 years (5 to 19 years) 10 years (5 to 18 years)
Median body condition score at testing (9 point
scale) (range)
5.0 (4 to 7) 5.5 (4 to 8)
Breed Domestic Short Hair 8, Burmese 8, Siamese 2,
Australian Mist 1, Russian X 1
Domestic Short Hair 15, Burmese 4, Oriental 1,
Abyssinian 1, Tonkinese 1
Median time in remission at testing (range) 101 days (10 days−4 years)1 Not applicable
% with normal fasting glucose concentration (≤ 6.5
mmol/L, 117 mg/dl)
80% (16/20)2 100% (22/22)
Mean fasting glucose concentration (range)
(mmol/L)
5.8 (3.9 to 8.4) 4.4 (2.8 to 6.1)
Mean glucose concentration at 2 h (range) (mmol/L) 19.6 (7.6 to 25.9)4 8.6 (3.2 to 16.3)
% with normal glucose tolerance test3 26% (5/19)4 100% (22/22)
Mean fPLI5 5.8 (1 to 16)6 2.3 (0.5 to 5.1)7
Mean fructosamine8 267 (197 to 347) 250 (190 to 305)7
1 Time from remission date (14 days after the date insulin administration ceased) to testing date.
2 The remaining four cats (20%) had fasting glucose concentrations of 6.6, 7.5, 7.8 and 8.4 mmol/L (119, 135, 140, and 151 mg/dl).
3 Normal glucose tolerance test defined as glucose concentration ≤ 6.5 mmol/L (117mg /dl) within three hours after 1 g/kg IV bolus of glucose administered.
4 The glucose tolerance test was not performed on one remission cat.
5 Laboratory reference range for fPLI was 0.1–3.5 ug/L within the normal range, 3.6–5.3 ug/L may indicate pancreatitis, and >5.4 ug/L consistent with pancreatitis.
6 fPLI results were not available for four remission cats.
7 fPLI and fructosamine results were not available for one control cat.
8 Laboratory reference range for fructosamine was 249–406 umol/L.
identified by the laboratory reference library and all 917 identified
and unidentified compounds from LCMS: 293 from RP_NEG
and 624 from RP_POS).
Principle component analysis revealed distinct clustering
of collective GCMS metabolic phenotypes between remission
and control cats with the first two components jointly highly
discriminatory between these groups (Figure 1). The first two
components accounted for 26% and 14%, respectively, of the
total variance of 61. For the first component, 12 compounds had
loadings above 0.2 (alanine, asparagine, glutamine, isoleucine,
leucine, methionine, phenylalanine, proline, serine, threonine,
tyrosine, and valine), and for the second component, eight
compounds had loadings above 0.2 (gluconic acid, glycerol,
glycerol-3-phosphate, phosphoric acid, threitol, threonic acid,
2,4-dihydroxybutanoic acid, and urea). The highest loadings
for the first two components were 0.22 and 0.25, respectively,
indicating that no single compound had a large influence on
either component. Negative loadings were all close to zero
(the most extreme was−0.14). These results show that when
considered collectively, concentrations of GCMS compounds
differ markedly between remission and control cats due to some
of these 61 compounds. For each of RP_NEG and RP_POS
LCMS compounds, collective metabolic phenotypes were not
discriminatory between remission and control cats. After
adjustment formultiple comparisons, serum concentrations of 22
compounds differed significantly (P < 0.05) between remission
and control cats, 16 of which were identified by the laboratory
reference library (Table 2). The remaining six metabolites
were not identified. Seventeen compounds (all RP_POS) were
FIGURE 1 | Principal component values from 41 cats for the first and second
components based on concentrations of 61 identified GCMS compounds
assessed in 20 cats in remission (hollow circles) and 21 healthy control cats
(solid circles).
not compared between remission and control cats because
concentrations had no or minimal variation between cats.
Metabolites Detected With GCMS
Fifteen identified GCMS metabolites differed significantly (P <
0.05) between remission and control cats: 11 amino acids, 1 fatty



































TABLE 2 | Means and estimated ratios of means for metabolites significantly different between control and remission cats (P adjusted for multiple comparisons < 0.05).
Metabolite Arithmetic mean
(SD)
Geometric mean Adjusted ratio of
geometric
means1 (95% CI)
P2 Adjusted ratio of geometric means1 for cats with
dietary data (16 remission cats and 17 control cats)
Remission














Alanine 0.22 (0.21) 0.56 (0.29) 0.15 0.47 0.29 (0.17 to 0.51) 0.01 0.29 (0.16 to 0.52) 0.16 (0.05 to 0.53) 0.27 (0.11 to 0.67)
Asparagine 0.02 (0.03) 0.08 (0.03) 0.01 0.07 0.16 (0.09 to 0.27) < 0.01 0.14 (0.08 to 0.24) 0.13 (0.04 to 0.40) 0.15 (0.06 to 0.34)
Aspartate 0.03 (0.04) 0.10 (0.09) 0.01 0.06 0.08 (0.04 to 0.17) < 0.01 0.07 (0.03 to 0.16) 0.03 (0.01 to 0.18) 0.04 (0.01 to 0.15)
Glutamine 0.08 (0.14) 0.59 (0.28) 0.01 0.49 0.01 (0.00 to 0.05) < 0.01 0.11 (0.00 to 0.34) 0.00 (0.00 to 0.14) 0.01 (0.00 to 0.03)
Glycine 0.33 (0.14) 0.17 (0.10) 0.29 0.14 2.09 (1.39 to 3.14) 0.04 2.22 (1.40 to 3.52) 2.8 (1.11 to 7.06) 2.82 (1.41 to 5.64)
Leucine 0.74 (0.72) 1.31 (0.44) 0.35 1.18 0.22 (0.10 to 0.45) 0.01 0.20 (0.09 to 0.47) 0.14 (0.13 to 0.16) 0.19 (0.05 to 0.69)
Methionine 0.10 (0.10) 0.16 (0.08) 0.07 0.15 0.37 (0.23 to 0.60) 0.01 0.34 (0.20 to 0.57) 0.26 (0.09 to 0.74) 0.28 (0.13 to 0.62)
Proline 0.05 (0.05) 0.10 (0.05) 0.02 0.09 0.23 (0.10 to 0.50) 0.03 0.21 (0.09 to 0.46) 0.05 (0.01 to 0.22) 0.15 (0.04 to 0.49)
Serine 0.27 (0.26) 0.60 (0.22) 0.15 0.56 0.27 (0.14 to 0.50) 0.01 0.26 (0.13 to 0.50) 0.10 (0.03 to 0.35) 0.18 (0.07 to 0.47)
Tyrosine 0.06 (0.04) 0.12 (0.03) 0.04 0.12 0.26 (0.15 to 0.45) < 0.01 0.24 (0.13 to 0.45) 0.08 (0.02 to 0.24) 0.16 (0.06 to 0.40)
Valine 0.76 (0.70) 1.32 (0.53) 0.42 1.15 0.27 (0.14 to 0.51) 0.01 0.26 (0.12 to 0.53) 0.13 (0.03 to 0.56) 0.21 (0.07 to 0.62)
GC-MS3 Fatty Acids
Octadecanoic acid 0.03 (0.02) 0.006 (0.02) 0.02 0.06 0.37 (0.27 to 0.50) < 0.01 0.35 (0.25 to 0.50) 0.30 (0.15 to 0.58) 0.37 (0.22 to 0.62)
GC-MS3 Sugars and Sugar Alcohols
Glucose 44.14 (10.38) 33.8 (5.76) 42.93 33.32 1.30 (1.12 to 1.50) 0.05 1.28 (1.10 to 1.49) 1.21 (0.89 to 1.64) 1.29 (1.02 to 1.63)
Xylitol 0.01 (0.02) 0.03 (0.01) 0.01 0.02 0.19 (0.10 to 0.36) < 0.01 0.15 (0.08 to 0.26) 0.10 (0.03 to 0.31) 0.15 (0.06 to 0.35)
GC-MS3 Other
Urea 4.39 (1.64) 2.66 (1.20) 4.10 2.45 1.70 (1.28 to 2.24) 0.02 1.77 (1.34 to 2.34) 2.02 (1.16 to 3.53) 1.85 (1.21 to 2.82)
LC-MS4
Carnitine 0.033 (0.014) 0.015 (0.009) 0.030 0.013 2.50 (1.80 to 3.48) < 0.01 2.76 (1.96 to 3.87) 2.43 (1.22 to 4.81) 2.86 (1.70 to 4.80)
1 Ratio of geometric mean for remission cats relative to that for control cats adjusted for cat age, breed (Burmese or non-Burmese), sex (male or female) and body condition score (95% CI not adjusted for multiple comparisons).
2 P-value adjusted for multiple comparisons (P-value not adjusted for multiple comparisons were all < 0.01).
3 Gas chromatography mass spectrometry; data were not available for one control cat.
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FIGURE 2 | Crude geometric means for 14 of the 16 metabolites that differed signified between remission cats (hollow bars; n = 20) and control cats (solid bar n =
22). Glucose (means 42.9 and 33.3, respectively) and urea (means 4.1 and 2.5, respectively) also differed significantly between remission and control cats. Each bar
shows the mean of the relative response ratios for each cat.
acid (stearic acid), 1 sugar (glucose), 1 sugar alcohol (xylitol), and
urea (Table 2, Figure 2).
Amino Acids and Derivatives
For most of the 11 amino acids (alanine, asparagine, aspartate,
glutamine, methionine, proline, serine, tyrosine, and the branch-
chain amino acids leucine, and valine), serum concentrations
were significantly less amongst cats in remission, with means
estimated to be more than 60% lower. In contrast, mean glycine
concentration was estimated to be more than two-fold higher
(Table 2). Most amino acid concentrations were negatively
correlated (−0.3< r<−0.7) with GTT results, either 2-h glucose
(for 8 amino acids) or time for glucose to return to baseline
(for 10 amino acids) (Table 3). Five amino acid concentrations
were negatively correlated with either casual blood glucose
and/or fasting blood glucose, and glycine was positively
correlated with these measures (Table 3). Concentrations of
other identified amino acids (glutamic acid, homoserine,
isoleucine, lysine, phylalanine, pyroglutamic acid, threonine, and
tryptophan) did not differ significantly between remission and
control cats.
Fatty Acids and Sterols
The mean concentration of one fatty acid, octadecanoic
(stearic) acid, was decreased by an estimated 63% in cats in
remission (Table 2), and was negatively correlated (−0.5 < r
< −0.7) with all glucose variables (Table 3). Concentrations
of other identified fatty acids and sterols (1-campesterol,
1-monohexadecanoylglycerol, 1-monooctadecanoylglycerol,
2-monooleoglycerol, 5-alpha-chloestan-3-ol, beta-sitosterol,
cholesterol, hexadecanoic acid, hexadecenoic acid,
octadecadienoic acid, octadecenoic acid, and tetradecanoate)
did not differ significantly between remission and
control cats.
Sugars and Sugar Alcohols
The mean concentration of glucose measured by GCMS was an
estimated 30% higher (P < 0.05) in remission cats (Table 2),
and as expected correlated with fasting glucose measured 3 h
after the metabolomics sample was taken using a hand-held
glucometer, and 2 h glucose and time for glucose to return
to baseline during GTT (Table 3). The mean concentration
of the sugar alcohol, xylitol, was an estimated 81% lower
(P < 0.01) in remission cats (Table 2), and was negatively
correlated (−0.4 < r < −0.5) with all glucose variables,
except casual blood glucose (Table 3). Concentrations of other
identified sugars (fructose, galactinol, inositol, maltose, and
threitol) did not differ significantly between remission and
control cats.
Organic Acids
Several organic acids were identified (2,4-dihydroxybutanoic
acid, 2-amino-butyric acid, 2-ketoglutaric acid, aconitic acid,
citric acid, fumaric acid, gluconic acid, glyceric acid, lactic
acid, malic acid, picolinic acid, pyruvic acid, succinic acid,
and threonic acid), but concentrations of these did not differ
significantly between remission and control cats.
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TABLE 3 | Correlation coefficients (and p-values for testing null hypotheses that the correlation is 0) for correlations between selected metabolites and each of casual,
fasting, and 2 h glucose, time for glucose to return to baseline, fPli and fructosamine.
Metabolite Plasma glucose concentrations Time for glucose to return to baseline fPLi Fructosamine
Casual Fasting 2 h
GC–MS Amino Acids
Alanine −0.37 −0.26 −0.46 −0.57 0.01 −0.16
P = 0.04 NS P = 0.01 P < 0.01 NS NS
Asparagine −0.34 −0.39 −0.55 −0.66 0.02 −0.23
NS P = 0.03 P <0.01 P <0.01 NS NS
Aspartate −0.34 −0.27 −0.35 −0.40 0.01 −0.22
NS NS NS P = 0.03 NS NS
Glutamine −0.44 −0.46 −0.59 −0.63 −0.15 −0.37
P = 0.02 P = 0.01 P <0.01 P <0.01 NS P = 0.04
Glycine 0.39 0.48 0.35 0.34 0.33 0.55
P = 0.03 P = 0.01 NS NS NS P <0.01
Leucine −0.37 −0.39 −0.43 −0.49 0.22 −0.23
P = 0.04 P = 0.03 P = 0.02 P = 0.01 NS NS
Methionine −0.22 −0.21 −0.28 −0.41 0.33 −0.25
NS NS NS P = 0.03 NS NS
Proline −0.33 −0.28 −0.44 −0.51 0.15 −0.17
NS NS P = 0.02 P = 0.01 NS NS
Serine −0.33 −0.22 −0.46 −0.52 0.06 −0.14
NS NS P 0.01 P <0.01 NS NS
Tyrosine −0.47 −0.44 −0.52 −0.58 0.05 −0.26
P = 0.01 P = 0.01 P <0.01 P <0.01 NS NS
Valine −0.39 −0.43 −0.40 −0.46 0.25 −0.34
P = 0.03 P = 0.02 P = 0.03 P = 0.01 NS NS
GC–MS Fatty Acids and Sterols
OctadecanoicAcid −0.52 −0.50 −0.69 −0.67 −0.31 −0.11
P <0.01 P <0.01 P <0.01 P <0.01 NS NS
GC–MS Sugars and Sugar Alcohols
Glucose 0.29 0.41 0.49 0.55 0.36 0.19
NS P = 0.02 P = 0.01 P <0.01 NS NS
Xylitol −0.34 −0.46 −0.46 −0.40 0.19 −0.34
NS P = 0.02 P = 0.01 P = 0.03 NS NS
GC–MS Other Metabolites
Urea 0.24 0.34 0.43 0.42 0.08 0.05
NS NS P = 0.02 P = 0.02 NS NS
LC–MS Metabolites
Carnitine 0.25 0.31 0.46 0.42 0.15 0.14
NS NS P = 0.01 P = 0.02 NS NS
Not significant (NS) indicates P > 0.05.
Other Compounds
The mean concentration of urea was an estimated 70% higher
(P < 0.05) in remission cats (Table 2). In further analysis,
urea remained significantly (P < 0.05) higher in remission
cats even after exclusion of six remission cats with IRIS stage
> 2 chronic kidney disease (creatinine ≥140 µmol/L and
USG ≤1.035)3 Urea was positively correlated (r = 0.4) with
both 2 h glucose and time for glucose to return to baseline
during GTT (Table 3). Concentrations of other identified
3International Renal Interest Society: http://www.iris-kidney.com
compounds (glycerol, glycerol-3-phosphate, phosphoric acid,
phosphoric acid monomethylester, pyrophosphate, serotonin,
and tocopherol) did not differ significantly between remission
and control cats.
Correlations Between Metabolites and fPLi
and Fructosamine
Only two identified GCMS metabolites were significantly
correlated with fructosamine (Table 3). The amino acid,
glutamine, had a negative correlation (r = −0.4), whilst glycine
was positively correlated (r = 0.6) with fructosamine. There
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were no significant correlations between any identified GCMS
metabolite and fPLI.
METABOLITES DETECTED WITH LCMS
Mean concentrations for seven metabolites differed significantly
between remission and control cats when analysed using LCMS,
although only one (the amino-acid derivative, carnitine) was
identified. The mean concentration of carnitine was estimated to
be 250% higher (P < 0.01) in remission cats (Table 2, Figure 2),
and was positively correlated with each of 2 h glucose and time
for glucose to return to baseline during GTT (r = 0.46 and 0.42,
respectively; Table 3).
Associations With Relapse Amongst
Remission Cats
Of the 20 remission cats enrolled in the study, 19 were monitored
for relapse; 5 of those relapsed 50, 58, 103, 230, and 257 days after
testing. Of the remaining 14 cats, 13 were monitored for between
270 and 1133 days (median 614 days), and 1 cat died at day
253. None of the metabolites that differed significantly between
remission and control cats was a significant (P < 0.05) predictor
of relapse.
Effects of Diet
Dietary information was available for 16/20 (80%) remission cats
and 17/22 (77%) control cats. Mean dietary protein content was
higher (50 vs. 31%) and mean carbohydrate content lower (25 vs.
40%) in remission cats and control cats, respectively, whilst mean
fat contents were similar (17 vs. 18%). Adjustment for either
dietary protein or dietary carbohydrate did not change whether
identified metabolites were increased or decreased, but in some
instances the difference between remission and control cats was
more pronounced after adjustment for protein intake (Table 2).
Carnitine was present in the diet of half of the remission cats, but
no control cats. However, the increase in mean serum carnitine
concentration in remission cats compared to controls was similar
amongst cats not fed carnitine (ratio of geometric means 3.11;
95% CI 1.85 to 5.22) to when all cats were included (Table 2).
DISCUSSION
A metabolomics (GCMS and LCMS) approach was used to
identify novel metabolites of diabetic cats in remission. The
plasma concentrations of many glucogenic amino acids were
markedly reduced in remission cats, except glycine which
was increased. Urea and carnitine were also increased, and
octadecanoic (stearic) acid was decreased. Associations were
found between identified metabolites and glycaemic measures
in this cohort of cats in remission, of which 74% continued to
display impaired glucose tolerance and 20% had mildly impaired
fasting glucose. None of the metabolites proved to be a predictor
of relapse, although they provide new insights into altered
metabolism in diabetes in cats.
In the current study, mean plasma glucose concentrations
assessed by GCMS analysis were an estimated 30% higher in cats
in diabetic remission compared to control cats, confirming blood
glucose measurements 3 h later using a handheld glucometer (4).
This increase in fasting blood glucose concentration in remission
cats is most likely due to increased hepatic gluconeogenesis as a
result of unresolved insulin resistance (17). On average, diabetic
cats are six times less sensitive to insulin compared to normal
cats (17). Hepatic gluconeogenesis, which is normally inhibited
by insulin, is increased in insulin resistance in cats (18). Based on
the findings of this current study, cats in diabetic remission have
a decrease in many glucogenic amino acids (alanine, asparagine,
aspartate, glutamine, methionine, proline, serine, tyrosine, and
valine), consistent with the hypothesis of increased consumption
for gluconeogenesis in these animals. Indeed, all of these amino
acids were negatively associated with casual and fasting blood
glucose, 2 h blood glucose and return to baseline during a GTT.
Alternatively, the decrease in glucogenic amino acids observed
in cats in remission might simply reflect a shift towards amino
acid metabolism due to decreased carbohydrate metabolism.
Lower amino acid concentrations may reflect increased oxidation
of amino acids as substrates in the tricarboxylic acid (TCA)
cycle, on a background of reduced glycolysis, as suggested in
human diabetics (19). Reduced concentrations of glucogenic
precursors alanine, glutamine, serine, glycine and arginine have
been previously reported in diabetic humans and mice (19, 20).
Altogether, the reduction in many glucogenic amino acids in cats
in diabetic remission in the current study supports the idea of
continued dysregulation of glucose and amino acid metabolism.
An unexpected result in the current study was glycine,
which was increased an estimated 2-fold in remission cats.
Glycine levels are decreased in humans with type 2 diabetes or
impaired glucose tolerance, with reduced glycine concentrations
being considered a risk factor for the development of type
2 diabetes in humans (8, 9, 21, 22). Low glycine has been
correlated with increased 2-h blood glucose concentration
following a GTT in humans, and with increased fasting and 2-
h glucose concentrations in rats (9, 23) Also in cats, glycine
is known to be an efficient gluconeogenic precursor, even
better than in rats (24). Therefore, increased glycine in cats in
remission suggest peculiar glycinemetabolism, perhaps unique to
diabetic remission. A possible explanation is increased glyoxylate
metabolism, with glycine being formed from glyoxylate via
transamination utilising alanine as a donor. In this regard, we
have noted abnormal glycolate-glyoxylate metabolism, together
with dysregulated glucose metabolism, in both senior obese
and Burmese cats at high risk of developing diabetes, although
in both these cat groups, plasma glycine was normal (5). In
humans, increased dietary glycine intake has beneficial effects
in obesity and type 2 diabetes, including improving insulin
sensitivity (25, 26). However, here in cats in diabetic remission,
glycine concentrations were positively correlated with both
casual and fasting glucose. Therefore, the functional significance
of increased glycine in remission cats is unclear.
Leucine and valine, two branched-chain amino acids
(BCAAs), were significantly decreased in remission cats. In
humans and diabetic mice, increases in BCAAs (including
isoleucine) are associated with impaired fasting glucose and type
2 diabetes (10, 20, 27). BCAAs are thought to modulate insulin
secretion, and increased circulating BCAAs may promote insulin
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resistance by disrupting insulin signalling in skeletal muscle (10).
Remission cats had decreased leucine and valine levels in spite of
impaired fasting glucose and delayed glucose tolerance. Obesity
has been linked to increased BCAAs in humans(22), and mean
body condition score of our remission cats was 5 (out of 9, range
5–7) and control cats was 5.5 (range 4–8) (23). However, body
condition was adjusted for in the comparison of remission and
control cats, so is unlikely to explain why leucine and valine were
reduced in remission cats.
High levels of saturated fatty acids are a risk factor for
diabetes in humans, and high dietary intake is associated with
obesity and increased risk of developing diabetes (28, 29).
Octadecanoic (stearic) acid, a saturated fatty acid, was the only
lipid significantly different between groups, being reduced in
remission cats and having negative correlations with glucose
parameters. This fatty acid was also decreased in Burmese cats
at higher risk of developing diabetes, and thus reductions in
stearic acid levels might reflect quite different lipid metabolism
in diabetic cats (5). However, feeding cats a stearic rich, high fat
diet increases hepatic lipid accumulation and other early signs
of liver damage (30). More work is required to investigate lipid
metabolism in obesity and diabetes in cats.
Urea was also increased in remission cats. Although a subset
of remission cats did have renal disease (thus decreased excretion
of urea), the increase in plasma urea was still significant after
analysis without these cats. In part, the increase in urea might
be associated with an increase in alanine metabolism through
the glucose-alanine cycle, which converts pyruvate in muscle
to alanine, which is then transported to the liver, where it is
then converted back to pyruvate and used as a substrate for
gluconeogenesis or a precursor for the TCA cycle (31). A by-
product of this cycle is urea, produced in the liver. In men,
urea was one of many markers found to be a discriminator of
impaired fasting glucose, and similarly in the cats in remission,
plasma urea showed a positive relationship with glucose results
in GTT (32).
Mean concentration of xylitol was decreased by an estimated
80% in remission cats, and xylitol was negatively correlated to
glucose variables. Diabetic rats fed a 10% xylitol solution exhibit
improved glucose tolerance and pancreatic islet morphology
(33, 34). Xylitol ingestion in dogs is potentially lethal, stimulating
insulin secretion, and causing marked hypoglycaemia, although
this has never been reported in cats (35). Further research is
needed to determine if impaired glucose tolerance results in
decreased xylitol, or if decreased xylitol results in impaired
glucose tolerance.
The mean concentration of the amino-acid derivative,
carnitine, was an estimated 250% higher in remission cats, and
was also positively correlated with glucose measures in GTT.
Carnitine is absorbed through dietary intake or is synthesised in
the liver, and is an essential cofactor of fatty acid metabolism,
assisting in the transport of acetyl Co-A out of mitochondria.
Accumulation of acetyl Co-A has been implicated in insulin
resistance in skeletal and cardiac muscle of humans and rodents
(36, 37). In human and rodent studies, supplementation with
carnitine improved glucose parameters in diabetic subjects
regardless of the route given (IV or oral) (36). Whilst 50% of
remission cats ate a diet with carnitine added, the increase in
serum carnitine in remission cats was found to be independent
of dietary carnitine.
Diet composition, in particular high protein content, has been
shown to alter metabolic profiles in healthy cats fed a specific
diet twice a day for 15 days with samples collected after an
overnight fast on the 16th day (38). However, the post-prandial
period in cats can be up to 24 h, and therefore, following an
overnight fast, cats were likely still in the post-prandial period,
which may account for the dietary differences seen in that study
(39). All cats in our study were fasted 24 h prior to testing,
which would be expected to remove any post-prandial effects
of diet. Most human studies reporting metabolomics data do
not limit patients to a specific diet providing adequate fasting
is observed, and veterinary studies using other modalities (even
clinical biochemistry) to measure metabolites in diseases such
as diabetes or obesity, typically either do not have all patients
on the same diet (8, 9, 27). Obviously, where there might be a
postprandial effect, either overnight or 24 h fasting is accepted as
sufficient to minimise the dietary effect.
Whilst diabetic diets (high in protein and lower in
carbohydrate) were recommended to owners of cats in diabetic
remission (excepting cases with renal disease, where a renal
diet was advised), there was no provision in this study to
supply specific food, and thus diet was left up to owner
discretion. Although the remission group in the current study
did have higher mean protein content in their diet (50 vs.
31% in the control cats), the metabolite results when adjusted
for diet showed either similar or even greater differences in
metabolites compared to remission cats. Requiring cats to
have eaten a specific diet would limit the suitability of the
metabolites discovered for future use as diagnostic measures in
veterinary clinics.
This study did not exclude cats based on the type of diabetes
present. Our aimwas to examine diabetic cats in remission, rather
than to confine the cohort to type 2 diabetics, because of the
difficulty in being confident of this diagnosis. Whilst the majority
(72%) of cats were presumed to have type 2 diabetes, screening
for other specific types of diabetes such as acromegaly was not
routinely performed. Although five cats had therapeutic doses of
glucocorticoids, these do not normally induce diabetes in cats,
and those with steroid-induced diabetes likely have underlying β-
cell dysfunction, which may be associated with the same process
causing type 2 diabetes. In humans diabetics, pre-existing β-cell
dysfunction causing defects in insulin secretion are normally
present when corticosteroid administration induces diabetes
(40). However, corticosteroid-induced diabetes is classified as
an “other specific type of diabetes” by the American Diabetes
Association, as it is possible that the underlying pathophysiologic
process is easier to reverse (41). Significantly higher remission
rates are reported in cats that had corticosteroids administered
in the 6 months prior to diagnosis (1). It has been suggested
that these cats should be classified as “other specific type”
of diabetes, but if they relapse following remission they are
classified as type 2. Of the four cats with previous corticosteroid
administration and without concurrent pancreatitis, only one
relapsed following additional corticosteroid administration for
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palliation of a spinal lesion. The major limitation of this study
was small sample size, which may have limited the ability to
detect some variables associated with relapse, if any associations
exist. Metabolomic analysis did not take into account the type
of diabetes prior to remission due to small numbers. A larger
scale study would allow for comparison of identified metabolites
between types of diabetes and control cats. Finally, limitations
on the total number of available authentic standards limited
the total number of metabolites able to be positively identified
by LCMS. This study focused on differences between cats in
diabetic remission and healthy control cats. Whilst outside the
scope of this study, a comparison between diabetic cats and
diabetic cats in remission would add further understanding to
this field.
In conclusion, this study shows that diabetic cats in remission
have major differences in broader metabolism, compared
to control cats. An improved understanding of abnormal
metabolism will enable future testing of markers related
to abnormal glucose metabolism and/or allow for targeted
therapies to be developed to improve glucose tolerance in
these cats.
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